RESEARCH PAPER
Clinical experience with dolutegravir: efficacy, safety, and tolerability
1
Department of Infectious Diseases, Centro Hospitalar Universitário do Porto, Porto, Portugal
Submission date: 2020-09-08
Final revision date: 2021-04-06
Acceptance date: 2021-04-07
Publication date: 2022-01-10
HIV & AIDS Review 2022;21(1):10-16
KEYWORDS
dolutegravirHIVantiretroviral agentsHIV integrase strand-transfer inhibitorslow-level viremiaviral blipsvirologic failure
TOPICS
ABSTRACT
Introduction:
Dolutegravir (DTG) is an effective antiretroviral drug, associated with rapid virologic responses. Intermittent viremia has been linked to a higher risk of virologic failure and immune activation.
Material and methods:
A retrospective, observational study of human immunodeficiency virus type 1 (HIV-1) infected adults who have started DTG between May 2015 and May 2017 was conducted, aiming to evaluate virologic responses. Baseline, 4-, 12-, 24-, and 48-week data were analyzed, including incidence of blips and low-level viremia (LLV), immunological progression and tolerability. The population was divided into three groups, including antiretroviral treatment (ART)-naïve, ART-experienced without virological failure (HIV-RNA < 200 copies/ml) at switch to DTG, and ART-experienced with virological failure (HIV-RNA ≥ 200 copies/ml) at switch to DTG.
Results:
Within the 227-patient population, 55 (24.2%) were ART-naïve and 172 (75.7%) switched from other regimens. Virologic suppression (< 50 copies/ml) at 48-week was observed in 92.7%, 88.4%, and 75% of naïve, ART-experienced without virological failure at switch, and ART-experienced with virological failure at switch patients, respectively. During follow-up, 4.9% of ART-experienced without virological failure patients had blips above 50 copies/ml, and 0.6% of them maintained LLV above 50 copies/ml.
Conclusions:
The use of dolutegravir in naïve patients was associated with a 92.7% rate of viral suppression at week 48. Experienced non-failing patients rarely developed intermittent viremia above 50 copies/ml.
Dolutegravir (DTG) is an effective antiretroviral drug, associated with rapid virologic responses. Intermittent viremia has been linked to a higher risk of virologic failure and immune activation.
Material and methods:
A retrospective, observational study of human immunodeficiency virus type 1 (HIV-1) infected adults who have started DTG between May 2015 and May 2017 was conducted, aiming to evaluate virologic responses. Baseline, 4-, 12-, 24-, and 48-week data were analyzed, including incidence of blips and low-level viremia (LLV), immunological progression and tolerability. The population was divided into three groups, including antiretroviral treatment (ART)-naïve, ART-experienced without virological failure (HIV-RNA < 200 copies/ml) at switch to DTG, and ART-experienced with virological failure (HIV-RNA ≥ 200 copies/ml) at switch to DTG.
Results:
Within the 227-patient population, 55 (24.2%) were ART-naïve and 172 (75.7%) switched from other regimens. Virologic suppression (< 50 copies/ml) at 48-week was observed in 92.7%, 88.4%, and 75% of naïve, ART-experienced without virological failure at switch, and ART-experienced with virological failure at switch patients, respectively. During follow-up, 4.9% of ART-experienced without virological failure patients had blips above 50 copies/ml, and 0.6% of them maintained LLV above 50 copies/ml.
Conclusions:
The use of dolutegravir in naïve patients was associated with a 92.7% rate of viral suppression at week 48. Experienced non-failing patients rarely developed intermittent viremia above 50 copies/ml.
REFERENCES (41)
1.
Todd S, Rafferty P, Walker E, et al. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. Int J STD AIDS 2017; 28: 1074-1081.
2.
van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-118.
3.
Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-743.
4.
Comi L, Maggiolo F. Abacavir + dolutegravir + lamivudine for the treatment of HIV. Expert Opin Pharmacother 2016; 17: 2097-2106.
5.
Churchill D, Waters L, Ahmed N, et al. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med 2016; 17 Suppl 4: s2-s104.
6.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/s....
7.
EACS. European AIDS Clinical Society. Guidelines version 9.0. 2017. Available at: https://www.eacsociety.org/med....
8.
Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-748.
9.
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-1818.
10.
Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27: 1771-1778.
11.
Curtis L, Nichols G, Stainsby C, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials 2014; 15: 199-208.
12.
Cid-Silva P, Llibre JM, Fernández-Bargiela N, et al. Clinical experience with the integrase inhibitors dolutegravir and elvitegravir in HIV-infected patients: efficacy, safety and tolerance. Basic Clin Pharmacol Toxicol 2017; 121: 442-446.
13.
Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS 2017; 31: 1853-1858.
14.
Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75: 990-996.
15.
Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc 2014; 17 (4 Suppl 3): 19490.
16.
Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-708.
17.
Patel DA, Snedecor SJ, Tang WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PLoS One 2014; 9: e105653.
18.
Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41: 1326-1332.
19.
Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72: 2422-2428.
20.
Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1030-1037.
21.
Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 2011; 204: 515-520.
22.
Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 2013; 57: 1489-1496.
23.
Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother 2016; 71: 1051-1055.
24.
Maggiolo F, Callegaro A, Cologni G, et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012; 60: 473-482.
25.
Eastburn A, Scherzer R, Zolopa AR, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 2011; 6: e26320.
26.
Taiwo B, Hunt PW, Gandhi RT, et al. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 63: 101-104.
27.
Reus S, Portilla J, Sanchez-Paya J, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr 2013; 62: 129-134.
28.
Zoufaly A, Kiepe JG, Hertling S, et al. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med 2014; 15: 449-457.
29.
Ruggiero A, Cozzi-Lepri A, Beloukas A, et al. Factors associated with persistence of plasma HIV-1 RNA during long-term continuously suppressive firstline antiretroviral therapy. Open Forum Infect Dis 2018; 5: ofy032.
30.
Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother 2014; 58: 3585-3598.
31.
Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202: 1553-1561.
32.
Nasi M, De Biasi S, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol 2017; 187: 44-52.
33.
Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: e44454.
34.
Margolick JB, Bream JH, Martinez-Maza O, et al. Frailty and circulating markers of inflammation in HIV+ and HIV– men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2017; 74: 407-417.
35.
Esber A, Polyak C, Kiweewa F, et al. Persistent low-level viremia predicts subsequent virologic failure: is it time to change the third 90? Clin Infect Dis 2019; 69: 805-812.
36.
Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 45: 483-493.
37.
Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS 2002; 16: 1521-1527.
38.
Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004; 18: 2075-2079.
39.
Kolber MA, Gabr AH, De La Rosa A, et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS 2002; 16: 537-542.
40.
Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis 2019; 68: 87-95.
41.
Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig 2015; 35: 211-219.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
